All Stories

  1. Urothelial genotoxicity of household chemicals in healthy canine urinary bladder organoids relative to observed urinary exposures in pet dogs
  2. Evidence-Based Medical Therapy for Mitral Regurgitation in Dogs
  3. Establishment and transcriptomic characterization of canine organoids from multiple tissues
  4. Retrospective Comparison of Outcomes From Septic Peritonitis of Gastrointestinal Versus Non‐Gastrointestinal Etiology in Dogs (2009–2022): 161 Cases
  5. A microfluidic platform for culturing and high-content imaging of adult stem cell-derived organoids
  6. Bioengineered gut bacterium synthesizing levodopa alleviates motor deficits in models of Parkinson’s disease
  7. Development of a Time-based Drug Screening Platform for Improved Clinical Translation
  8. A Roadmap for the Future of Systems Biology in Cancer Research
  9. Retrospective Evaluation of Treatment and Survival of Blunt Trauma‐Associated Pneumothorax in Dogs: 89 Cases (2018–2022)
  10. Retrospective Evaluation of the Incidence and Risk Factors Associated With the Development of a Hepatopathy in Xylitol Ingestion: 95 Dogs (2018–2022)
  11. Interdisciplinary research seeks treatments and cures for diseases of animals and humans
  12. SUN-056 The National Biorepository and Resource for Pituitary Neuroendocrine Tumor Translational Research (BioPitNeT)
  13. Establishing a Canine Urothelial Organoid Repository: A Platform for Comparative and Translational Carcinoma Studies
  14. A comprehensive pharmacodynamic dataset reconciles 50 years of laboratory and clinical knowledge
  15. Innovative In Vitro-In Silico Platform for Dose-Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based Approach
  16. Letter Regarding “Recommendations for a Complete Reporting of Statistical Methods in Veterinary Pharmacology”
  17. Optimizing First‐Line Therapeutics in Non‐Small Cell Lung Cancer: Insights From Joint Modeling and Large‐Scale Data Analysis
  18. Experimental Methods for Establishing and Maintaining Canine Bladder Cancer Organoids
  19. Evolving value and validity of animal models in veterinary therapeutic research: Impact of scientific progress
  20. Restorative Effects of Synbiotics on Colonic Ultrastructure and Oxidative Stress in Dogs with Chronic Enteropathy
  21. OrganoidChip+: a Microfluidic Platform for Culturing, Staining, Immobilization, and High-Content Imaging of Adult Stem Cell-Derived Organoids
  22. Penicillin and Gentamicin Concentrations in the Uterine Fluid of Non‐Pregnant Mares Following a Single Intrauterine Infusion
  23. Frequency and Characterization of Rare Histologic Subtypes in Canine Invasive Urothelial Carcinoma
  24. Incidence of hypernatremia in dogs treated with multi-dose activated charcoal for acute toxicant ingestion: multi-center retrospective study (2018–2023)
  25. Pharmacokinetic evaluation and bioavailability of KPT-335 (Verdinexor) in cats
  26. Su1305: DUODENAL DNA METHYLATION PROFILES IN DOGS WITH CHRONIC INFLAMMATORY ENTEROPATHY TREATED WITH NOVEL SYNBIOTIC
  27. <span style="mso-bidi-font-weight: bold;">Spontaneous Canine Disease Models in Biomedical Science: A One Health Path to Predictive Drug Development
  28. Development and Characterization of Chicken Lung Organoids for Future In Vitro Modeling of Avian Influenza Virus-Host Cell Interaction
  29. A Preclinical Model to Assess Intestinal Barrier Integrity Using Canine Enteroids and Colonoids
  30. The association between non-depolarizing neuromuscular blockade agents and survival to discharge in dogs undergoing mechanical ventilation: a multi-center retrospective study of 227 dogs (2010–2020)
  31. Retrospective Evaluation of Complications Associated With Surgically Placed Gastrostomy Tubes in Dogs (2010–2020): 133 Cases
  32. Effects of a Western Diet on Colonic Dysbiosis, Bile Acid Dysmetabolism and Intestinal Inflammation in Clinically Healthy Dogs
  33. Incidence of hypernatremia in dogs treated with single dose activated charcoal for acute toxicant ingestion: multi-center retrospective study (2018–2023)
  34. A Novel Preclinical Model to Assess Intestinal Barrier Integrity Using Canine Enteroids and Colonoids
  35. A preliminary investigation in dogs to evaluate for post-anesthetic lung ultrasound findings suggestive of atelectasis
  36. A multi-stage feature selection method to improve classification of potential super-agers and cognitive decliners using structural brain MRI data—a UK biobank study
  37. Utilization of peripheral glucose and lactate differences in the diagnosis of feline arterial thromboembolism: a multi-center study
  38. Dose‐exposure‐response of CARDALIS® (benazepril/spironolactone) on the classical and alternative arms of the renin‐angiotensin‐aldosterone system in healthy dogs
  39. Frequency and progression of azotemia during acute and chronic treatment of congestive heart failure in cats
  40. Treatment of Canine Myxomatous Mitral Valve Disease:Current and Future Approaches
  41. University of Georgia College of Veterinary Medicine’s Precision One Health Initiative improves animal and human health by developing alternative models of disease
  42. Cisplatin-Induced Metabolic Responses Measured with Raman Spectroscopy in Cancer Cells, Spheroids, and Canine-Derived Organoids
  43. Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity
  44. 166 Development of non-model organoids in animal research: A paradigm shift in in vitro models
  45. Pharmacokinetics of isavuconazonium sulfate and its active metabolite isavuconazole in healthy dogs
  46. Evaluating the Bias of Two Point-of-Care Glucometers for Calves and Ewes: Awareness for Ruminant Practitioners
  47. Systemic absorption and gastrointestinal adverse effects from topical ketorolac and diclofenac ophthalmic solutions in healthy dogs
  48. Renin-Angiotensin Aldosterone System Modulation and Cardiovascular-Kidney-Metabolic Health
  49. Population Pharmacokinetics and Absolute Oral Bioavailability of Lasalocid after Single Intravenous and Intracrop Administration in Laying Hens
  50. Abstract PR002: Sarcomatoid Histological Variants of Canine Muscle-Invasive Bladder Cancer: Transcription Factor Activation Highlights Pathways of Epithelial-Mesenchymal Transformation Similar to Humans
  51. Retrospective evaluation of the prevalence and risk factors associated with red blood cell transfusions in cats with urethral obstruction (2009–2019): 575 cases
  52. Tu1739 MICRORNAS AS POTENTIAL BIOMARKERS FOR DIAGNOSIS AND MONITORING CHRONIC INFLAMMATORY ENTEROPATHY IN DOGS
  53. Randomized comparison between a forced air system and warm water bath for resuscitation of neonatal hypothermic calves with or without oral administration of caffeine
  54. Preclinical Modeling of Metabolic Syndrome to Study the Pleiotropic Effects of Novel Antidiabetic Therapy Independent of Obesity
  55. Experimental Methods for Establishing and Maintaining Canine Bladder Cancer Organoids
  56. A machine learning approach for potential Super‐Agers identification using neuronal functional connectivity networks
  57. Evaluation of different media compositions promoting hepatocyte differentiation in the canine liver organoid model
  58. Letter regarding “Fuzapladib in a randomized controlled multicenter masked study in dogs with presumptive acute onset pancreatitis”
  59. Comparison of Traditional Didactic Versus Additional Hands-On Simulation Training in the Performance of Basic Life Support in Veterinary Students—A Prospective, Blinded, Randomized Study
  60. Comprehensive characterization of the effect of mineralocorticoid receptor antagonism with spironolactone on the renin-angiotensin-aldosterone system in healthy dogs
  61. Establishment and characterization of turtle liver organoids provides a potential model to decode their unique adaptations
  62. Effect of amlodipine on the circulating renin‐angiotensin‐aldosterone system in healthy cats
  63. Genetic Factors of Alzheimer’s Disease Modulate How Diet is Associated with Long-Term Cognitive Trajectories: A UK Biobank Study
  64. Adult Animal Stem Cell-Derived Organoids in Biomedical Research and the One Health Paradigm
  65. Leveraging the predictive power of 3D organoids in dogs to develop new treatments for man and man’s best friend
  66. A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic Control
  67. Retrospective evaluation of admission total plasma protein as a predictor of red blood cell transfusion requirement in dogs diagnosed with traumatic and nontraumatic hemoabdomen: 90 dogs (2009–2019)
  68. Exploring the benefits of in-diet versus repeated oral dosing of saracatinib (AZD0530) in chronic studies: insights into pharmacokinetics and animal welfare
  69. A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic Control
  70. Exploring the Potential Links Between Gut Bacteria-Related Metabolites and the Risk of Cardiovascular Diseases
  71. Role of the tumour microenvironment in bladder cancer pathogenesis and value of the reverse translational approach: a tale of two species
  72. Effect of the Probiotic Bacillus subtilis DE-CA9TM on Fecal Scores, Serum Oxidative Stress Markers and Fecal and Serum Metabolome in Healthy Dogs
  73. Retrospective comparison of outcomes in septic peritonitis with or without closed-suction abdominal drainage in 115 dogs (2009–2019)
  74. Phenylbutazone concentrations in synovial fluid following administration via intravenous regional limb perfusion in the forelimbs of six adult horses
  75. Gene Editing and Gene Therapy in Oncology
  76. Echocardiographic caudal vena cava measurements in healthy cats and in cats with congestive heart failure and non-cardiac causes of cavitary effusions
  77. Blood product usage and factors associated with transfusions in cats with hemoperitoneum: 33 cases (2018–2022)
  78. OrganoidChip facilitates hydrogel-free immobilization for fast and blur-free imaging of organoids
  79. Changes of Enterocyte Morphology and Enterocyte: Goblet Cell Ratios in Dogs with Protein-Losing and Non-Protein-Losing Chronic Enteropathies
  80. Increased drug concentration and repeated eye drop administration as strategies to optimize topical drug delivery: A fluorophotometric study in healthy dogs
  81. O62 | Population pharmacokinetics of sodium salicylate in chickens and turkeys – New insights into the drug's non‐linear elimination
  82. O89 | A novel biologically relevant canine in vitro model for the study of intestinal inflammation
  83. O59 | Breakthrough: A first‐in‐class virtual simulator for dose optimization of ACE inhibitors in veterinary cardiology
  84. O60 | Comparison of intestinal barrier integrity in conventional 2D cell lines and canine duodenal enteroids
  85. P51 | Evaluation of potential anti‐inflammatory and barrier‐enhancing effects of indoles on the canine duodenum using intestinal organoids
  86. O90 | Lung organoids as a novel model to study the pathogenesis of swine respiratory diseases
  87. O88 | Prediction of treatment response using canine urine‐derived bladder cancer organoids
  88. O63 | Population pharmacokinetics and absolute oral bioavailability of lasalocid ionophore in laying hens
  89. Concentrations of penicillin and gentamicin following intrauterine administration of two compounded formulations
  90. Leveraging Data from Spontaneous Animal Disease Models to Streamline Pharmaceutical Research: A Tale of Two Species
  91. Comprehensive characterization of the effect of mineralocorticoid receptor antagonism with spironolactone on the renin-angiotensin-aldosterone system in healthy dogs.
  92. Sa1767 SYNBIOTIC-IGY THERAPY MODULATES THE MUCOSAL MICROBIOME AND INFLAMMATORY INDICES IN DOGS WITH CHRONIC INFLAMMATORY ENTEROPATHY: A RANDOMIZED, CONTROLLED PILOT TRIAL
  93. Canine Intestinal Organoids as a Novel In Vitro Model of Intestinal Drug Permeability: A Proof-of-Concept Study
  94. Canine Intestinal Organoids as a Novel In Vitro Model of Intestinal Drug Permeability: A Proof-of-Concept Study
  95. Abstract 2509: Similar variant histology and immune cell infiltration in canine and human muscle-invasive bladder cancer
  96. Exploring the secrets of super-aging: a UK Biobank study on brain health and cognitive function
  97. Understanding the background and clinical significance of the WHO, WOAH, and EMA classifications of antimicrobials to mitigate antimicrobial resistance
  98. Pharmacokinetics of intramuscular maropitant in pigs (Sus scrofa domesticus)
  99. Breakthrough: a first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine
  100. Characterization of the First Turtle Organoids: A Model for Investigating Unique Adaptations with Biomedical Potential
  101. Dose–response of benazepril on biomarkers of the classical and alternative pathways of the renin–angiotensin–aldosterone system in dogs
  102. Retrospective evaluation of the effect of inhalant anesthesia on complications and recurrence rates in feline urethral obstruction
  103. Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves
  104. Ionophore coccidiostats – disposition kinetics in laying hens and residues transfer to eggs
  105. Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer Using Large Database Reveals Potential Benefits of Scheduling Optimization
  106. Retrospective Comparison of Outcomes in Septic Peritonitis With or Without Closed-Suction Abdominal Drainage in 115 Dogs (2009-2019)
  107. Synbiotic-IgY Therapy Modulates the Mucosal Microbiome and Inflammatory Indices in Dogs with Chronic Inflammatory Enteropathy: A Randomized, Double-Blind, Placebo-Controlled Study
  108. Pilot safety evaluation of doxorubicin chemotherapy combined with non-specific immunotherapy (Immunocidin®) for canine splenic hemangiosarcoma
  109. Comparison of the pharmacokinetics of continuous and intermittent infusions of ampicillin-sulbactam in dogs with septic peritonitis
  110. Breakthrough: A First-In-Class Virtual Simulator for Dose Optimization of ACE Inhibitors in Translational Cardiovascular Medicine
  111. Breakthrough: A First-In-Class Virtual Simulator for Dose Optimization of ACE Inhibitors in Veterinary Cardiology
  112. Linear external skeletal fixation applied in minimally invasive fashion for stabilization of nonarticular tibial fractures in dogs and cats
  113. Culture and characterization of canine and feline corneal epithelial organoids: A new tool for the study and treatment of corneal diseases
  114. Retrospective evaluation of risk factors for development of kidney injury after parenteral furosemide treatment of left‐sided congestive heart failure in dogs
  115. Kinetics and minimal inhibitory concentrations of ceftiofur in tear film following extended-release parenteral administration (Excede®) in dogs
  116. Bioenergetic and vascular predictors of potential super-ager and cognitive decline trajectories—a UK Biobank Random Forest classification study
  117. Ketogenic diets in healthy dogs induce gut and serum metabolome changes suggestive of anti‐tumourigenic effects: A model for human ketotherapy trials
  118. Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs
  119. Differential Transcriptomic Profiles Following Stimulation with Lipopolysaccharide in Intestinal Organoids from Dogs with Inflammatory Bowel Disease and Intestinal Mast Cell Tumor
  120. A Multi-Tissue Comparison and Molecular Characterization of Canine Organoids
  121. Letter regarding “Gastrointestinal foreign bodies in pet pigs: 17 cases”
  122. Evaluation of the Use of External Skeletal Fixation in Minimally Invasive Fashion for the Treatment of Non-articular Tibial Fractures
  123. Abstract 3092: Urine-derived urinary carcinoma organoids: A novel tool for providing new insights into human and canine bladder cancer treatment
  124. Retrospective Evaluation of Clinical Bleeding in Dogs With Anticoagulant Rodenticide Toxicity—A Multi-Center Evaluation of 62 Cases (2010–2020)
  125. Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors
  126. Using machine learning to predict COVID-19 infection and severity risk among 4510 aged adults: a UK Biobank cohort study
  127. SGLT2 Inhibitors and Potential Applications in Treating Metabolic Syndrome
  128. Comparisons of plasma and fecal pharmacokinetics of danofloxacin and enrofloxacin in healthy and Mannheimia haemolytica infected calves
  129. Circulating renin‐angiotensin‐aldosterone system activity in cats with systemic hypertension or cardiomyopathy
  130. Canine Intestinal Organoids in a Dual-Chamber Permeable Support System
  131. Canine Intestinal Organoids in a Dual-Chamber Permeable Support System
  132. Computed Tomographic Evaluation of Mid-thoracic Vertebral Corridors in Normal French Bulldogs
  133. Standardization and Maintenance of 3D Canine Hepatic and Intestinal Organoid Cultures for Use in Biomedical Research
  134. Standardization and Maintenance of 3D Canine Hepatic and Intestinal Organoid Cultures for Use in Biomedical Research
  135. Differential Transcriptomic Profiles in Canine Intestinal Organoids Following Lipopolysaccharide Stimulation
  136. Suspected primary hyperreninism in a cat with malignant renal sarcoma and global renin‐angiotensin‐aldosterone system upregulation
  137. Multiomic analysis defines the first microRNA atlas across all small intestinal epithelial lineages and reveals novel markers of almost all major cell types
  138. Albumin in Tears Modulates Bacterial Susceptibility to Topical Antibiotics in Ophthalmology
  139. Harnessing the Biology of Canine Intestinal Organoids to Heighten Understanding of Inflammatory Bowel Disease Pathogenesis and Accelerate Drug Discovery: A One Health Approach
  140. Current diagnostics for chronic enteropathies in dogs
  141. Clinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study
  142. 109 Diet-induced Clinical Responsiveness of Translational Dog Model for Human Western Diet (WD)-related Disease Research
  143. Pharmacokinetics of Pantoprazole and Pantoprazole Sulfone in Goats After Intravenous Administration: A Preliminary Report
  144. Pharmacokinetics of tulathromycin in pregnant ewes (Ovis aries) challenged with Campylobacter jejuni
  145. CULTURE AND MAINTENANCE OF URINE-DERIVED, 3-DIMENSIONAL CANINE TRANSITIONAL CELL CARCINOMA ORGANOIDS
  146. Retrospective evaluation of a dose‐dependent effect of angiotensin‐converting enzyme inhibitors on long‐term outcome in dogs with cardiac disease
  147. Computed tomography evaluation of proposed implant corridors in canine thoracic vertebrae
  148. Inflammation, negative affect, and amyloid burden in Alzheimer’s disease: Insights from the kynurenine pathway
  149. Focused ultrasound of the caudal vena cava in dogs with cavitary effusions or congestive heart failure: A prospective, observational study
  150. Corrigendum: Comparative Pharmacokinetics of Meloxicam Between Healthy Post-partum vs. Mid-lactation Dairy Cattle
  151. Gene Editing and Gene Therapy: Entering Uncharted Territory in Veterinary Oncology
  152. Radiation exposure associated with percutaneous fluoroscopically guided lag screw fixation for sacroiliac luxation in dogs
  153. Short‐term outcomes of 59 dogs treated for ilial body fractures with locking or non‐locking plates
  154. Su124 HOMOLOGY DIRECTED REPAIR IN CANINE DUODENAL ENTEROIDS TO MIMIC THE WILD-TYPE P-GLYCOPROTEIN MUTATION
  155. Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics
  156. Clinical Efficacy of Prebiotics and Glycosaminoglycans versus Placebo In Dogs with Food Responsive Enteropathy Receiving a Hydrolyzed Diet: A Pilot Study
  157. Effect of prazosin on feline recurrent urethral obstruction
  158. Presentation, Clinical Pathology Abnormalities, and Identification of Gastrointestinal Parasites in Camels (Camelus bactrianus and Camelus dromedarius) Presenting to Two North American Veterinary Teaching Hospitals. A Retrospective Study: 1980–2020
  159. Influence of Schirmer strip wetness on volume absorbed, volume recovered, and total protein content in canine tears
  160. A Multi-Institutional Retrospective Analysis of Toceranib Phosphate for Presumed or Confirmed Canine Aortic Body Chemodectomas
  161. Letter to the editor regarding “Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial”
  162. Emerging Roles of Urine-Derived Components for the Management of Bladder Cancer: One Man’s Trash Is Another Man’s Treasure
  163. Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer
  164. Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration
  165. Genetic Factors of Alzheimer’s Disease Modulate How Diet is Associated with Long-Term Cognitive Trajectories: A UK Biobank Study
  166. Emerging Roles of Urine-Derived Components for the Management of Bladder Cancer: One Man’s Trash is Another Man’s Treasure
  167. Genetics and Immunopathogenesis of Chronic Inflammatory Enteropathies in Dogs
  168. Impact of diurnal variation, sex, tear collection method, and disease state on tear protein levels in dogs
  169. Tear Film Pharmacokinetics and Systemic Absorption Following Topical Administration of 1% Prednisolone Acetate Ophthalmic Suspension in Dogs
  170. Pharmacokinetics of Oral Prednisone at Various Doses in Dogs: Preliminary Findings Using a Naïve Pooled-Data Approach
  171. Considerations in the extrapolation of drug toxicity between humans and dogs
  172. Evaluation of a Pasteurella multocida Respiratory Disease Induction Model for Goats (Capra aegagrus hircus)
  173. Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats
  174. Determination of the milk pharmacokinetics and depletion of milk residues following intramammary administration of cephapirin sodium in lactating dairy goats
  175. Serum albumin and total protein concentration in the tear film of horses with healthy or diseased eyes
  176. Comparative Pharmacokinetics of Meloxicam Between Healthy Post-partum vs. Mid-lactation Dairy Cattle
  177. Pharmacokinetics of Intravenous, Intramuscular, Oral, and Transdermal Administration of Flunixin Meglumine in Pre-wean Piglets
  178. Neuroinflammation, Depressive Affect, and Amyloid Burden in Alzheimer’s Disease: Insights from the Kynurenine Pathway
  179. Effects of the estrous cycle and pregnancy status on cardiovascular variables in healthy bitches
  180. An eye on the dog as the scientist's best friend for translational research in ophthalmology: Focus on the ocular surface
  181. Treatment With Hydrolyzed Diet Supplemented With Prebiotics and Glycosaminoglycans Alters Lipid Metabolism in Canine Inflammatory Bowel Disease
  182. Impact of acute conjunctivitis on ocular surface homeostasis in dogs
  183. Walking in the Light: How History of Physical Activity, Sunlight, and Vitamin D Account for Body Fat—A UK Biobank Study
  184. An Eye on the Dog as the Scientist’s Best Friend for Translational Research in Ophthalmology: Focus on the Ocular Surface
  185. Sa1976 POLYPHENOLS REVERSE THE PATHOLOGIC EFFECTS OF PALMITIC ACID AND HIGH FAT DIET IN CANINE ENTEROIDS
  186. Recapitulation of the accessible interface of biopsy-derived canine intestinal organoids to study epithelial-luminal interactions
  187. Evaluation of dose-response effects of short-term oral prednisone administration on clinicopathologic and hemodynamic variables in healthy dogs
  188. Harnessing The Biology of Intestinal Organoids To Accelerate Drug Discovery in Inflammatory Bowel Disease: A One Health Approach
  189. Serum Vitamin B12, and Related MTRR and Cubilin Genotypes, Predict Neural Outcomes across the AD Spectrum
  190. A Retrospective Clinical Investigation of the Safety and Adverse Effects of Pantoprazole in Hospitalized Ruminants
  191. Investigation of Schirmer tear test-1 for measurement of tear production in cats in various environmental settings and with different test durations
  192. Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
  193. Apparent total tract digestibility, fecal characteristics, and blood parameters of healthy adult dogs fed high-fat diets
  194. Albumin Levels in Tear Film Modulate the Bioavailability of Medically-Relevant Topical Drugs
  195. CSF glucose tracks regional tau progression based on Alzheimer's disease risk factors
  196. Glucocorticoid and dietary effects on mucosal microbiota in canine inflammatory bowel disease
  197. Kinetics of Fluorescein in Tear Film After Eye Drop Instillation in Beagle Dogs: Does Size Really Matter?
  198. Nerve growth factor in dogs: Assessment of two immunoassays and selected ocular parameters following a nicergoline challenge per os
  199. In vitro Cytotoxicity and Pharmacokinetic Evaluation of Pharmacological Ascorbate in Dogs
  200. Aging-related changes in fluid intelligence, muscle and adipose mass, and sex-specific immunologic mediation: A longitudinal UK Biobank study
  201. Re: “Evaluation of Enrofloxacin for Use in Cryopreservation of Zebu Bull (Bos indicus) Semen” by Ishaq et al. (Biopreserv Biobank 2019;[Epub ahead of print]; DOI: 10.1089/bio.2018.0133)
  202. Pharmacokinetic Modeling of Ceftiofur Sodium Using Non-linear Mixed-Effects in Healthy Beagle Dogs
  203. Comparative pharmacokinetics of meloxicam between healthy postpartum versus mid-lactation dairy cows
  204. Fluorophotometric Assessment of Tear Volume and Turnover Rate in Healthy Dogs and Cats
  205. Clinicopathologic, hemodynamic, and echocardiographic effects of short-term oral administration of anti-inflammatory doses of prednisolone to systemically normal cats
  206. Nonlinear mixed‐effects pharmacokinetic modeling of the novel COX‐2 selective inhibitor vitacoxib in dogs
  207. Pharmacokinetic Modeling of Ceftiofur Sodium Using Nonlinear Mixed-Effects in Healthy Beagle Dogs
  208. Histamine-Induced Conjunctivitis and Breakdown of Blood–Tear Barrier in Dogs: A Model for Ocular Pharmacology and Therapeutics
  209. Microbiota-Related Changes in Unconjugated Fecal Bile Acids Are Associated With Naturally Occurring, Insulin-Dependent Diabetes Mellitus in Dogs
  210. The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review
  211. A reduced Gompertz model for predicting tumor age using a population approach
  212. Effects of experimentally induced respiratory disease on the pharmacokinetics and tissue residues of tulathromycin in meat goats
  213. Indoleamine-pyrrole 2,3-dioxygenase-1 (IDO-1) mRNA is over-expressed in the duodenal mucosa and is negatively correlated with serum tryptophan concentrations in dogs with protein-losing enteropathy
  214. Interleukin‐13 and interleukin‐33 mRNA are underexpressed in the duodenal mucosa of German Shepherd dogs with chronic enteropathy
  215. Paper spray high-resolution accurate mass spectrometry for quantitation of voriconazole in equine tears
  216. Tear Fluid Pharmacokinetics Following Oral Prednisone Administration in Dogs With and Without Conjunctivitis
  217. Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
  218. 449 – High Fat Ketogenic Diet Decreases Serum Lipid Metabolites in Healthy Dogs
  219. Sa1098 – Molecular Response of Canine Intestinal Organoids to Gastrointestinal Nematode Extracellular Vesicles
  220. Su1812 – Treatment with Hydrolyzed Diet Supplemented with Prebiotics and Glycosaminoglycans Improves Abnormalities in Lipid Metabolism in a Canine Model of Inflammatory Bowel Disease
  221. Su2043 – A Novel Canine Intestinal Organoid Model to Characterize Dose-Exposure-Response of Chemotherapeutic Drugs
  222. Derivation of adult canine intestinal organoids for translational research in gastroenterology
  223. CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies
  224. A Review of Relevant Therapeutic Targets for the Management of Congestive Heart Failure in Dogs: Present and Future Directions
  225. Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer
  226. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation
  227. The Role of the Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review
  228. Pharmacokinetics of Ertapenem in Sheep (Ovis aries) with Experimentally Induced Urinary Tract Infection
  229. Workshop Report: USP Workshop on Exploring the Science of Drug Absorption
  230. Population Modeling of Tumor Growth Curves, the Reduced Gompertz Model and Prediction of the Age of a Tumor
  231. Correlating Gastrointestinal Histopathologic Changes to Clinical Disease Activity in Dogs With Idiopathic Inflammatory Bowel Disease
  232. CAR T-Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds against Hematological Malignancies
  233. Relative Oral Bioavailability of Two Amoxicillin–Clavulanic Acid Formulations in Healthy Dogs: A Pilot Study
  234. Clinical features of cats with aqueous tear deficiency: a retrospective case series of 10 patients (17 eyes)
  235. Adult Canine Intestinal Derived Organoids: A Novel In Vitro System for Translational Research in Comparative Gastroenterology
  236. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs
  237. Sacubitril/valsartan (LCZ696) Significantly Reduces Aldosterone and Increases cGMP Circulating Levels in a Canine Model of RAAS Activation
  238. Comparative plasma and interstitial fluid pharmacokinetics and tissue residues of ceftiofur crystalline-free acid in cattle with induced coliform mastitis
  239. Adverse reactions to fentanyl transdermal patches in calves: a preliminary clinical and pharmacokinetic study
  240. Impact of Flow Rate, Collection Devices, and Extraction Methods on Tear Concentrations Following Oral Administration of Doxycycline in Dogs and Cats
  241. Population variability in animal health: Influence on dose-exposure-response relationships: Part II: Modelling and simulation
  242. Mo1059 - Comparison of Endoscopically (Egd/Colo) Procured Enteroids and Colonoids from Normal Dogs and Dogs with Naturally Occurring Chronic Enteropathies (IBD)
  243. Effects of short-term anti-inflammatory glucocorticoid treatment on clinicopathologic, echocardiographic, and hemodynamic variables in systemically healthy dogs
  244. Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation
  245. Effect of tear collection on lacrimal total protein content in dogs and cats: a comparison between Schirmer strips and ophthalmic sponges
  246. Comparison of milk and plasma pharmacokinetics of meloxicam in postpartum versus mid-lactation Holstein cows
  247. Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences
  248. Intestinal Stem Cells to Advance Drug Development, Precision, and Regenerative Medicine: A Paradigm Shift in Translational Research
  249. Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics
  250. Model-Based Reverse Translation Between Veterinary and Human Medicine: The One Health Initiative
  251. Pharmacokinetics and adverse reactions to fentanyl transdermal patches in healthy and hospitalized calves
  252. Tear fluid collection in dogs and cats using ophthalmic sponges
  253. Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats
  254. Position Paper: EUFEPS Network on Veterinary Medicines Initiative
  255. Multiple comparison procedure and modeling: a versatile tool for evaluating dose-response relationships in veterinary pharmacology - a case study with furosemide
  256. Mathematical modeling and simulation in animal health - Part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment
  257. Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics
  258. Chronobiology and Pharmacologic Modulation of the Renin–Angiotensin–Aldosterone System in Dogs: What Have We Learned?
  259. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs
  260. FIRST-IN-CLASS ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR LCZ696 MODULATES THE DYNAMICS OF THE RENIN CASCADE AND NATRIURETIC PEPTIDES SYSTEM WITH SIGNIFICANT REDUCTION OF ALDOSTERONE EXPOSURE
  261. Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs
  262. Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis
  263. Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology
  264. Animal Health Modeling & Simulation Society: a new society promoting model-based approaches in veterinary pharmacology
  265. Response to letter from Atkinset al. Capturing the dynamics of systemic Renin‐Angiotensin‐Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs
  266. Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs
  267. Pharmacokinetics of extravascular maropitant citrate in swine